Earlier detection of GDM may possibly prevent pregnancy complications. Thus, the identification of sensitive and specific biomarkers is important, which may offer potential for risk prediction and intervention strategies. Ace Therapeutics can provide researchers engaged in biomarkers development of GDM with more efficient function analysis and overall therapy services.
The research on screening biomarkers in the early stage of GDM has gradually is important, involving markers related to the etiology and pathophysiology of GDM, metabolomics markers, etc. Routine GDM biomarkers (plasma glucose, insulin, C-peptide, homeostatic model assessment of insulin resistance, and sex hormone-binding globulin) can differentiate between healthy pregnant women and those with GDM.
Immune spectrum in lean and obese adipose tissue (Man, Kevin et al. 2022)
| Novel Biomarkers | Description |
| Afamin | Afamin is a vitamin E-binding protein found in human plasma, which plays a role in the antiapoptotic cellular processes associated with oxidative stress. |
| ANGPTL8 | Angiopoietin-like protein 8 is involved in lipid and glucose homeostasis, and its concentrations were found to be higher under conditions of GDM than normal pregnancy. |
| Galanin | Galanin is a neuropeptide that reduces insulin resistance and improves glucose uptake. |
| VAP-1 | Vascular adhesion protein 1 (VAP-1) is a glycoprotein that plays a role in inflammation and oxidative stress. |
| FABP4 | Fatty acid-binding protein 4 (FABP-4) is a protein highly expressed in adipocytes. |
| Fetuin-A or AHSG | It is a glycoprotein that is produced by the liver and adipose tissue, and can be secreted by the placenta during pregnancy. |
| EVs | Extracellular vesicles (EVs) are small vesicles released into the extracellular space with the ability to reach the blood circulation. |
| Maternal microbiota | The microbiome also participate in the pathogenesis of several metabolic disorders, the composition of the maternal oral or gut microbiota could be a biomarker for GDM. |
Effective biomarkers are of great significance for early prediction of GDM. Ace Therapeutics can provide the biomarker development services for gestational diabetes mellitus. Our services include but not limited to the followings.
Highly Customizable
One-stop Services
High Quality
Professional Team
Ace Therapeutics offers cost-effect and high-quality research services related to GDM therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.
